- Home
- CRGX vs GNLX Comparison
CRGX vs GNLX Comparison
Compare CRGX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- GNLX
- Stock Information
- Founded
- CRGX 2021
- GNLX 2001
- Country
- CRGX United States
- GNLX United States
- Employees
- CRGX N/A
- GNLX N/A
- Industry
- CRGX
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- GNLX Health Care
- Exchange
- CRGX Nasdaq
- GNLX Nasdaq
- Market Cap
- CRGX 213.5M
- GNLX 184.4M
- IPO Year
- CRGX 2023
- GNLX 2023
- Fundamental
- Price
- CRGX $4.02
- GNLX $2.96
- Analyst Decision
- CRGX Hold
- GNLX Strong Buy
- Analyst Count
- CRGX 7
- GNLX 4
- Target Price
- CRGX $4.67
- GNLX $17.75
- AVG Volume (30 Days)
- CRGX 763.5K
- GNLX 138.3K
- Earning Date
- CRGX 05-16-2025
- GNLX 05-06-2025
- Dividend Yield
- CRGX N/A
- GNLX N/A
- EPS Growth
- CRGX N/A
- GNLX N/A
- EPS
- CRGX N/A
- GNLX N/A
- Revenue
- CRGX N/A
- GNLX N/A
- Revenue This Year
- CRGX $58.18
- GNLX N/A
- Revenue Next Year
- CRGX N/A
- GNLX N/A
- P/E Ratio
- CRGX N/A
- GNLX N/A
- Revenue Growth
- CRGX N/A
- GNLX N/A
- 52 Week Low
- CRGX $3.00
- GNLX $1.60
- 52 Week High
- CRGX $25.45
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- GNLX 54.28
- Support Level
- CRGX $3.97
- GNLX $2.26
- Resistance Level
- CRGX $4.66
- GNLX $3.06
- Average True Range (ATR)
- CRGX 0.20
- GNLX 0.31
- MACD
- CRGX -0.05
- GNLX 0.04
- Stochastic Oscillator
- CRGX 6.25
- GNLX 78.42
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.